Butylparaben included in ECHA’s SVHC Candidate List
The European Chemicals Agency (ECHA) has updated its Candidate List of Substances of Very High Concern (SVHCs) and included 4 new substances – three that are toxic to reproduction and one endocrine disruptor – Butylparaben, used as preservative in cosmetic products. Now, this list contains 209 substances that may have serious adverse effects on people or the environment.


In cosmetics and personal care products, Butylparaben is used as a preservative and masking agent. According to the European Cosmetic Regulation No. 1223/2009, Butylparaben is included in the list of preservatives allowed in cosmetic products (Annex V to Regulation), subject to the restrictions laid down. Butylparaben may be used as a preservative in cosmetics at a maximum concentration of 0.14% (as acid) in ready for use preparation. The use of this ingredient is not allowed in leave-on products designed for application on the nappy area of children under three years of age.

In 2011, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion on Parabens. The SCCS was of the opinion that the use of Butylparaben and Propylparaben as preservatives in finished products was safe to the consumer, as long as the sum of their individual concentrations did not exceed 0.19%.

In 2019, the Cosmetic Ingredient Review (CIR) Expert Panel has assessed the safety of Parabens in cosmetic products, including Butylparaben, and concluded that they were safe (except Benzylparaben) as cosmetic ingredients in the present practices of use and concentration described in the safety assessment report and when the sum of the total parabens in any given formulation does not exceed 0.8%.


The European Chemicals Agency (ECHA) Candidate List of Substances of Very High Concern (SVHCs) has been updated with 4 new substances and now contains 209 substances that may have serious effects on people or the environment. Most of the compounds present in the Candidate List of SVHCs are carcinogenic, mutagenic or toxic to reproduction.

1-Vinylimi­dazole, 2-Methylim­idazole and Dibutylb­is(pentane-2,4-dionato-O,O’)tin, used in industrial processes to produce polymers, were included in the list due to reprotoxic effects;

Butylparaben was included due to its endocrine-disrupting properties, which can be hazardous to human health.

Since the date of the substances inclusion in the Candidate List of SVHCs (June 25, 2020), producers and importers of articles or products including these substances have six months to notify ECHA. From January 2021, it will be mandatory for companies to notify the Agency, via ECHA’s upcoming SCIP database if their articles or products contain substances of concern from this list at levels above 0.1% weight by weight (w/w). On addition, sufficient information to costumers and consumers must be provided by a supplier of articles or products containing a Candidate List substance above 0.1% w/w to allow safe use.

As advised by ECHA, companies are urged to check their legal obligations relating to the safe use of these substances and to seek substitution of substances included in the SVHC Candidate List by safer alternatives.


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products
  2. Scientific Committee on Consumer Safety (SCCS) – Opinion on Parabens, COLIPA nº P82, 2011
  3. Scientific Committee on Consumer Safety (SCCS) – Opinion on Parabens – Updated request for a scientific opinion on propyl- and butylparaben, 2013
  4. Cosmetic Ingredient Review (CIR) Expert Panel – Amended Safety Assessment of Parabens as Used in Cosmetics, 2019
  5. European Chemicals Agency (ECHA) – Candidate List update: Four new hazardous chemicals to be phased out (ECHA/PR/20/05)
  6. European Chemicals Agency (ECHA) – Candidate List of substances of very high concern for Authorisation (published in accordance with Article 59(10) of the REACH Regulation)


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »